Carvedilol phosphate hemihydrate (BM 14190 phosphate hemihydrate) is a non-selective β/α-1 blocker^[1]. Carvedilol phosphate hemihydrate inhibits lipid peroxidation with an IC₅₀ of 5 μM. Carvedilol phosphate hemihydrate is a multiple action antihypertensive agent with potential use in angina and congestive heart failure^[2]. Carvedilol phosphate hemihydrate is an autophagy inducer that inhibits the NLRP3 inflammasome^[3].

β/α-1 adrenergic receptor^[1]
IC50: 5 μM (lipid peroxidation)^[2]
Autophagy^[3]

Superoxide generation by activated human neutrophils in vitro is inhibited by Carvedilol with an IC₅₀ of 28 μM. Carvedilol is shown to scavenge oxygen free radicals in a cell-free system with an IC₅₀ of 25 μM^[2].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

513.48

C₂₄H₃₀N₂O_8.5P

610309-89-2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Eggertsen R, et al. Acute haemodynamic effects of carvedilol (BM 14190), a new combined beta-adrenoceptor blocker and precapillary vasodilating agent, in hypertensive patients. Eur J Clin Pharmacol. 1984;27(1):19-22.

  [2]. Feuerstein GZ, et al. Myocardial protection by the novel vasodilating beta-blocker, carvedilol: potential relevance of anti-oxidant activity. J Hypertens Suppl. 1993 Jun;11(4):S41-8.

  [3]. Wong WT, et al. Repositioning of the β-Blocker Carvedilol as a Novel Autophagy Inducer That Inhibits the NLRP3 Inflammasome. Front Immunol. 2018 Aug 22;9:1920.